Jacob Asset Management of New York’s Arbutus Biopharma ABUS Stock Holding History

Jacob Asset Management of New York’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-187,400	Closed	-$437K	–	65
2022 Q4	$437K	Sell	187,400 -32,600	-15%	-$78K	0.53%	46
2022 Q3	$420K	Hold	220,000	–	–	0.46%	45
2022 Q2	$596K	Buy	220,000 +20,000	+10%	+$51.2K	0.6%	40
2022 Q1	$596K	Sell	200,000 -70,000	-26%	-$214K	0.36%	51
2021 Q4	$1.05M	Sell	270,000 -70,000	-21%	-$272K	0.47%	48
2021 Q3	$1.46M	Hold	340,000	–	–	0.53%	47
2021 Q2	$1.03M	Buy	340,000 +80,000	+31%	+$248K	0.34%	64
2021 Q1	$866K	Buy	+260,000	New	+$1M	0.34%	64

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacob Asset Management of New York's ABUS Position: Q1 2023 in Review

Jacob Asset Management of New York sold out of Arbutus Biopharma (ABUS) in Q1 2023, closing a stake of 187,400 shares — an estimated $437K sold.

Jacob Asset Management of New York first reported a position in ABUS in Q1 2021 and held it in 8 quarters. The position peaked at $1.46M in Q3 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q1 2023.

Jacob Asset Management of New York reported no remaining Arbutus Biopharma position as of Q1 2023 after selling out during the quarter.
Jacob Asset Management of New York sold 187,400 Arbutus Biopharma shares in Q1 2023, an estimated $437K.
Jacob Asset Management of New York first reported a position in Arbutus Biopharma in Q1 2021 and held it in 8 quarters.
Jacob Asset Management of New York's Arbutus Biopharma position peaked at $1.46M in Q3 2021.
122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2023.

Based on Jacob Asset Management of New York's 13F filing for Q1 2023, filed 11 May 2023.